DOCSLIB.ORG

Biographical Sketch

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

BIOGRAPHICAL SKETCH Name: Happi T. Christian Position/Title: Professor & Director, World Bank funded African Center of Excellence for Genomics of Infectious Diseases (ACEGID) eRA Commons Username: CTHAPPI Current Working Addresses: 1. Department of Biological Sciences, College of Natural Sciences, Redeemers’ University, Ede, Osun Sate, Nigeria. 2. Office of the Director, African Center of Excellence for Genomics of Infectious Diseases (ACEGID), Redeemer’s University, Ede, Osun State, Nigeria. 3. Office of the Director, Directorate of Research, Innovations and Partnerships (DRIPs), Redeemer’s University, Ede, Osun State, Nigeria. Current Employer (s): Redeemers’ University, Ede, Osun State, Nigeria. Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA. EDUCATION/TRAINING INSTITUTION AND LOCATION DEGREE YEAR(s) FIELD OF STUDY Harvard University, School of Public Postdoctoral Fellow 2000-2003 Molecular Biology Health, Boston, MA, USA University of Ibadan, Nigeria PhD 2000 Molecular Parasitology University of Ibadan, Nigeria M.Sc 1995 Molecular Parasitology University of Yaounde, Cameroon B.Sc (Hons) 1992 Biochemistry A. Positions and employments 2017- Director, Directorate of Research, Innovation and Partnerships, Redeemer’s University, Ede, Osun State, Nigeria. 2013-2018- Visiting Professor, Harvard University, Department of Organismic and Evolutionary Biology, Cambridge, Massachusetts, USA. 2012- 2016: Dean, College of Postgraduate Studies, Redeemer’s University, Ede, Osun State, Nigeria. 2012- Present: Senior Associate Member, The Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA. 2011- Present: Professor of Molecular Biology and Genomics, Department of Biological Sciences, College of Natural Sciences, Redeemers’ University, Ede, Osun State, Nigeria. 2011-Present: Fellow, Exxon-Mobil Corp, USA, Malaria Leadership Programme, Harvard Malaria Initiative, Harvard University, Boston, MA, USA. 2010-2012: Consultant and Technical Expert, International Atomic Energy Agency, AFRA Programme. 2009-2012: Honorary Senior Research Fellow, Division of Infections and Immunity, School of Medicine, University of Glasgow, Scotland, United Kingdom. 2009-Present: Visiting Professor, Harvard University, Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA, USA. 2007- present: Adjunct Faculty, Department of Pharmacology and Therapeutics, College of Medicine, University of Ibadan, Ibadan, Nigeria. 2006- Visiting Faculty, Department of Preventive Medicine, Faculty of Medicine, Federal University of Rio de Janeiro, Brazil. 2004-2009: Research Fellow, Department of Immunology and Infectious Diseases, Harvard School of Public Health, Harvard University, Boston, MA, USA. 2003-2012: Committee member and Temporary advisor, WHO/TDR Transfection Technology Network. 2003-2012: Principal Investigator, Malaria Research Laboratories, IMRAT, College of Medicine, University of Ibadan, Nigeria. 2002-2013: Visiting Research Scientist, Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Springs, MD, USA. 2002-2009: Nigerian National Coordinator, International Atomic Energy Agency (IAEA) RAF/0625/UNDP project Monitoring Drug Resistance to Malaria and Tuberculosis. 2001 to 2005: WHO/TDR Molecular Biologist Consultant, MIM/TDR Antimalarial Drugs Resistance Network in Africa. 2000 to 2003: Post-doctoral Research Fellow, Department of Immunology and Infectious Diseases, Harvard School of Public Health, Harvard University, Boston, MA, USA. 1997-2000: Junior Research Fellow, Malaria Research Laboratories, PIMRAT, College of Medicine, University of Ibadan, Nigeria. B. Honors and Awards. 2016- National Universities Commission Award for the Best Nigerian Academic Researcher in the field of Life Sciences and Medicine. 2015- Vice-Chancellor’s Hero Award, Redeemer’s University 10th Anniversary. 2015- Best Researcher Award, Redeemer’s University 10th Anniversary. 2014-2018 World Bank Grant Award to establish the African Centre of Excellence of Genomics of Infectious Diseases (ACEGID). 2 2013-2017 USA, NIH Grant Award to Characterize Fevers of Unknown Origin through Microbial Metagenomics. 2011-2016 Exxon-Mobil Corp. USA, Harvard University Malaria Leadership Fellowship Award (USA). 2011- 2011, Merle A. Sande Health Leadership Award (Accordia Foundation, USA). 2010-2015 USA, NIAID Grant Award to study Host Genetic Factors in Resistance to Lassa fever. 2010-2014 USA, NIH Grant Award to study Host Pathogen Evolution in Lassa fever. 2010- Scholarship to attend the Second Annual Course on Point-of-Care Diagnostics for Global Health, University of Washington Seattle (USA). 2010- Boroughs Wellcome and Bill & Melinda Gates Awards (USA). 2009-2014 USA, NIAID Grant to study the Roles of Protective or Pathogenic B cell Epitopes in Human Lassa Fever. 2009-2014 Wellcome Trust Research Grant Award (UK). 2009- 2011 European Union-Developing Countries Clinical Trials Partnership (EDCTP) Senior Research Fellowship Award (The Hague, Netherlands). 2008- Chair, Scientific Advisory Committee Africa Health Research Organization (AHRO) (Ghana). 2007-2011 NIH/Fogarty International Centre Research Collaboration Grant Award. (NIH, USA). 2007- Turner Biosciences Research Grant Award (USA). 2005-2008 WHO/TDR Plasmodium falciparum Pathogenesis and Applied Genomics Research Grant Award (World Bank/ UNICEF/WHO/TDR). 2005-2006 International Society of Infectious Diseases (ISID) Research Grant Award (USA). 2004-2005 Research Award for Microarrays Analysis of Plasmodium falciparum Genome (MR4, USA). 2004 Chair, Molecular Parasitology session, 50th Annual Meeting and Anniversary of the American Society of Tropical Medicine and Hygiene, Philadelphia, Pennsylvania, USA. 2003-2006 NIH/Fogarty International Center Research Collaboration Grant Award (NIH, USA). 2000-2003 WHO/TDR Postdoctoral Research Fellowship Award (World Bank/UNICEF/WHO/TDR). 1999 Award of the Best Postgraduate Student, University of Ibadan (Nigeria). 1998 Wellcome Trust Travel Award to attend the 1st Gordon Conference on Malaria (Oxford, UK). 1995 Award of the Best International Student, University of Ibadan (Nigeria). 1994-1997 Organization of African Unity (OAU), PhD Scholarship Award. 1988-1993 Cameroon Government Scholarship. C. Membership of Learned Society. 1. Member Advisory Board, 2016 World Innovation Summit for Health Conference, Doha, Qatar 2. Member, International Scientific Organizing Committee, 9th Pan-African MIM Conference (Senegal, 2017) 3 3. Member, Scientific Advisory Committee, Keystone Symposia Africa (Keystone Symposia USA) 4. Member Scientific Advisory Board, NIH funded BRAINS Project, Harvard University-University of Lagos, Nigeria 5. Member Scientific Advisory Board, NIH funded STAMINA Project, Harvard University-University of Jos, Nigeria 6. Member, Wellcome Trust-CIDRAP Ebola Vaccine Team B (2014) 7.Board Member, African Health Research Organization (AHRO), Ghana 8. Member, USA National Institutes of Health (NIH) International Centers of Infectious Diseases Research (ICIDR) Review Committee. (2014) 9. Member, USA National Institutes of Health (NIH) Centers of Excellence for Translational Research (CETR) Review Committee and Special Emphasis Panel. (2013). 10. Senior Associate Member, Broad Institute of Harvard and MIT 11. Member Steering Committee H3 Africa Consortium 12. Member, International Scientific Advisory Board, Accordia Global Health Foundation, Washington, DC, USA. (2011-2014). 13. Member of the African Academy of Science. (2004-Date) 14. International Scientific Committee Member, 4th Pan-African MIM conference (Cameroon). 15. Member of the Royal Society of Tropical Medicine, UK. (2001-date) 16. Member of the American Society of Tropical Medicine and Hygiene, USA. (2000-date) 17. Foundation member, Worldwide Antimalarial drugs Resistance Network [WWARN] (USA). D. Peer-Review. Member of Editorial Board/ Reviewer for Internationally Peer-reviewed Journals including: 1. Acta Tropica (Sweden); 2. African Journal of Medicine and Medical Sciences (Nigeria); 3. American Journal of Tropical Medicine and Hygiene (USA); 4. Annals of Tropical Medicine and Parasitology (UK); 5. Antimicrobial Agents and Chemotherapy (USA); 6. BMC Infectious Diseases (UK); 7. Drug Design, Development and Therapy (USA); 8. Emerging Infectious Diseases (USA); 9. Experimental Parasitology (USA); 10. Genome Biology (UK) 11. Infectious Disease News (USA); 12. International Journal of Parasitology (Australia); 13. Journal of Bacteriology and Parasitology (USA); 14. Journal of Infectious Diseases (USA); 15. Journal of Postgraduate Medicine (Canada); 16. Journal of Travel Medicine (USA); 17. Lancet Infectious Diseases (UK); 18. Malaria Journal (UK); 4 19. Parasitology Research (Germany); 20. Parasitology International (Japan) 21. Pharmacogenetics and Pharmacogenomics (Australia); 22. PLOS Genetics (USA) 23. PLOS Infectious Diseases (USA); 24. PLOS Medicine (USA); 25. PLOS One (USA); 26. Science (USA) 27. The Open Tropical Medicine Journal (USA); 28. The Medical Letter (USA); 29. Transactions of the Royal Society of Tropical Medicine and Hygiene (UK); 30. Tropical Medicine and International Health (UK). E. Selected Peer-reviewed Publications (Selected out of >150 in Reverse Chronological Order). 1. Gytis Dudas, Luiz Max Carvalho, Trevor Bedford, Andrew J. Tatem, Guy Baele, Nuno R. Faria, Daniel J. Park, Jason T. Ladner, Armando Arias, Danny Asogun, Filip Bielejec, Sarah L. Caddy, Matthew Cotton, Jonathan D’Ambrozio, Simon Dellicour,
Recommended publications
  • Nigeria Hit by Unprecedented Lassa Fever Outbreak Leslie Roberts

    Nigeria Hit by Unprecedented Lassa Fever Outbreak Leslie Roberts

    NEWS At Olorgesailie in Kenya, big hand axes (left) gave way INFECTIOUS DISEASE to smaller, more precise blades and points (right). more extreme. More than 80% of mammal Nigeria hit by unprecedented species had vanished and new kinds of el- ephants, pigs, foxes, and springboks gathered at tree-lined streams. MSA tools—relatively Lassa fever outbreak sophisticated blades and points that would have been hafted onto spears—were plentiful. As efforts to contain it mount, researchers are racing to find The site yielded no human fossils in this out what is driving this year’s surge in cases and deaths key time frame, so researchers can’t be sure who the new toolmakers were. But discover- ies elsewhere offer a strong hint. For years By Leslie Roberts Already, Nigeria’s fragile health care sys- archaeologists had thought the MSA tools tem is overwhelmed. The one dedicated were too old to have been made by our spe- y early January, it was clear some- Lassa fever ward in the country at Irrua cies. Then, last year, fossils resembling H. sa- thing “really, really extraordinary” Specialist Teaching Hospital in Edo state piens were found near MSA tools and dated was going on in Nigeria, says Lorenzo has just 24 beds. Without access to proper to nearly 300,000 years ago at Jebel Irhoud Pomarico of the Alliance for Interna- training and personal protective equip- in Morocco (Science, 9 June 2017, p. 993)— tional Medical Action (ALIMA). Cases ment, health care workers continue to timing that fits the Olorgesailie chronology. of Lassa fever, a rare viral hemor- become infected—by now 16 cases have Features of the MSA tools also suggest they Brhagic disease, were skyrocketing across the been reported, with one additional death.
  • August 2019 Vol 25, No 8, August 2019

    August 2019 Vol 25, No 8, August 2019

    ® August 2019 Pregnancy and Maternal Health Pregnancy Vol 25, No 8, August 2019 EMERGING INFECTIOUS DISEASES Pages 1445–1624 DEPARTMENT OF HEALTH & HUMAN SERVICES MEDIA MAIL Public Health Service POSTAGE & FEES PAID Centers for Disease Control and Prevention (CDC) Mailstop D61, Atlanta, GA 30329-4027 PHS/CDC Official Business Permit No. G 284 Penalty for Private Use $300 Return Service Requested Gift of George N. and Helen M. Richard, 1964. Image © The Metropolitan Museum of Art. Image source: Art Resource, NY Resource, Art source: Image Art. of Museum Metropolitan The © Image 1964. Richard, M. Helen and N. George of Gift . Oil on canvas; 28 1/2 in x 35 7/8 in/72.4 cm x 91.1 cm. cm. 91.1 x cm in/72.4 7/8 35 x in 1/2 28 canvas; on Oil . (1890) First Steps, after Millet after Steps, First Vincent van Gogh (1853–1890). (1853–1890). Gogh van Vincent ISSN 1080-6040 Peer-Reviewed Journal Tracking and Analyzing Disease Trends Pages 1445–1624 EDITOR-IN-CHIEF D. Peter Drotman ASSOCIATE EDITORS EDITORIAL BOARD Paul M. Arguin, Atlanta, Georgia, USA Barry J. Beaty, Fort Collins, Colorado, USA Charles Ben Beard, Fort Collins, Colorado, USA Martin J. Blaser, New York, New York, USA Ermias Belay, Atlanta, Georgia, USA Christopher Braden, Atlanta, Georgia, USA David M. Bell, Atlanta, Georgia, USA Arturo Casadevall, New York, New York, USA Sharon Bloom, Atlanta, Georgia, USA Kenneth G. Castro, Atlanta, Georgia, USA Richard Bradbury, Atlanta, Georgia, USA Vincent Deubel, Shanghai, China Mary Brandt, Atlanta, Georgia, USA Christian Drosten, Charité Berlin, Germany Corrie Brown, Athens, Georgia, USA Isaac Chun-Hai Fung, Statesboro, Georgia, USA Charles H.
  • Four Global Commissions in the Wake of Ebola

    Four Global Commissions in the Wake of Ebola

    Georgetown University Law Center Scholarship @ GEORGETOWN LAW 2016 Toward a Common Secure Future: Four Global Commissions in the Wake of Ebola Lawrence O. Gostin Georgetown University Law Center, [email protected] Oyewale Tomori Nigeria Academy of Sciences Suwit Wibulpolprasert Ministry of Public Health, Nonthaburi, Thailand Ashish K. Jha Harvard T.H. Chan School of Public Health Julio Frenk University of Miami See next page for additional authors This paper can be downloaded free of charge from: https://scholarship.law.georgetown.edu/facpub/1775 http://ssrn.com/abstract=2790862 13(5) Plos Med. 1-15 (May 19, 2016) This open-access article is brought to you by the Georgetown Law Library. Posted with permission of the author. Follow this and additional works at: https://scholarship.law.georgetown.edu/facpub Part of the Health Law and Policy Commons, Health Policy Commons, International Humanitarian Law Commons, Public Health Commons, and the Virus Diseases Commons Authors Lawrence O. Gostin, Oyewale Tomori, Suwit Wibulpolprasert, Ashish K. Jha, Julio Frenk, Suerie Moon, Joy Phumaphi, Peter Piot, Barbara Stocking, Victor J. Dzau, and Gabriel M. Leung This article is available at Scholarship @ GEORGETOWN LAW: https://scholarship.law.georgetown.edu/facpub/1775 POLICY FORUM Toward a Common Secure Future: Four Global Commissions in the Wake of Ebola Lawrence O. Gostin1*, Oyewale Tomori2, Suwit Wibulpolprasert3, Ashish K. Jha4, Julio Frenk5, Suerie Moon6, Joy Phumaphi7, Peter Piot8, Barbara Stocking9, Victor J. Dzau10, Gabriel M. Leung11 1 O’Neill Institute for National and Global Health Law, Georgetown University, Washington, DC, United States of America, 2 Nigeria Academy of Sciences, Lagos, Nigeria, 3 Ministry of Public Health, Nonthaburi, Thailand, 4 Harvard T.H.
  • Peter Sands, M.P.A. (Chair) Is a Senior Fellow at the Mossavar-Rahmani Center for Business and Government at Harvard Kennedy School

    Peter Sands, M.P.A. (Chair) Is a Senior Fellow at the Mossavar-Rahmani Center for Business and Government at Harvard Kennedy School

    Peter Sands, M.P.A. (Chair) is a senior fellow at the Mossavar-Rahmani Center for Business and Government at Harvard Kennedy School. He is also lead non-executive director of the Board of the United Kingdom’s Department of Health. Mr. Sands was Group Chief Executive of Standard Chartered Bank from November 2006 to June 2015. He joined the Board of Standard Chartered PLC as Group Finance Director in May 2002. Before his appointment as Group Chief Executive he was responsible for Finance, Strategy, Risk and Technology and Operations. Prior to joining Standard Chartered, Mr. Sands was a director with worldwide consultants McKinsey & Company. He had been with McKinsey since 1988 where he worked extensively in the banking and technology sectors in a wide range of international markets. He was elected a partner in 1996 and became a director in 2000. Prior to joining McKinsey, he worked for the United Kingdom’s Foreign and Commonwealth Office. Mr. Sands graduated from Oxford University and holds a Master’s in Public Administration from Harvard University, where he was a Harkness Fellow. Oyewale Tomori, D.V.M., Ph.D. (Vice Chair) is President of the Nigerian Academy of Science and pioneer Vice-Chancellor of Redeemer’s University, Nigeria. He is a Fellow of the Academy of Science of Nigeria, a Fellow of the College of Veterinary Surgeons of Nigeria, Fellow of the Royal College of Pathologists of the United Kingdom, and Fellow of the American Society of Tropical Medicine and Hygiene. Dr. Tomori received his D.V.M. from the Ahmadu Bello University in 1971 and his Ph.D.
  • Nigeria Is Poised to Become a Hub for Genetics Research, but a Few Stubborn Challenges Block the Way

    Nigeria Is Poised to Become a Hub for Genetics Research, but a Few Stubborn Challenges Block the Way

    Feature THE NEXT CHAPTER FOR AFRICAN GENOMICS Nigeria is poised to become a hub for genetics research, but a few stubborn challenges block the way. By Amy Maxmen 350 | Nature | Vol 578 | 20 February 2020 ©2020 Spri nger Nature Li mited. All ri ghts reserved. ©2020 Spri nger Nature Li mited. All ri ghts reserved. n the affluent, beach-side neighbour- meaning that dangerous pathogens could hoods of Lagos, finance and technology evade detection until an outbreak is too big entrepreneurs mingle with investors at to contain easily. art openings and chic restaurants. Now But Nigeria’s genetics revolution could just biotech is entering the scene. Thirty- as soon sputter as soar. Although the coun- four-year-old Abasi Ene-Obong has try is Africa’s largest economy, its research been traversing the globe for the past budget languishes at 0.2% of gross domestic six months, trying to draw investors and product (GDP). Biologists therefore need to Icollaborators into a venture called 54Gene. rely on private investment or on funding from Named to reflect the 54 countries in Africa, outside Africa. This threatens continuity: one the genetics company aims to build the con- of the largest US grants to Nigerian geneticists, tinent’s largest biobank, with backing from through a project known as H3Africa, is set to Silicon Valley venture firms such as Y Com- expire in two years. There are other challenges. binator and Fifty Years. The first step in that Human research in Africa requires copious effort is a study, launched earlier this month, communication and unique ethical consid- to sequence and analyse the genomes of eration given the vast economic disparities 100,000 Nigerians.
  • Ihr Committee Members Polio

    Ihr Committee Members Polio

    Biographies of the members of, and advisers to, the IHR Emergency Committee concerning ongoing events and context involving transmission and international spread of poliovirus Professor Helen Rees (CHAIR) GCOB OBE MB BChir MA(CANTAB) MRCGP DRCOG DCH, Executive Director, Wits Reproductive Health and HIV Institute, University of Witwatersrand, Johannesburg, South Africa Professor Rees is the Chairperson of the Board of the South African Health Products Regulatory Authority. She has served on and chaired many national and global scientific committees and boards. She was the Chair of the WHO’s Strategic Advisory Group of Experts on Immunisation (SAGE) and she now chairs the WHO’s African Regional Technical Advisory Group on Immunisation (RITAG). Since 2014 Professor Rees has been the Chair of the Emergency Committee regarding the international spread of poliovirus. From 2015 to 2016, she was a member of the Review Committee on the Role of the International Health Regulations (2005) in the Ebola Outbreak and Response tasked with making recommendations to WHO about steps required to improve the global response to public health emergencies and is a member of the IHR Emergency Committee on Yellow Fever. She was the Chair of the WHO SAGE Committee on the Use of Vaccines in Humanitarian Emergencies and is now the Co-Chair of the WHO SAGE Committee on Ebola vaccines as well as chairing the WHO’s Maternal Influenza Immunisation Advisory Review Committee. She is a member of the WHO SAGE Committee evaluating progress towards the Decade of Vaccines, and a member of the WHO SAGE Measles and Rubella Working Group. Professor Rees is a member of the Gavi Board and the Gavi Programme and Policy Committee, and chairs the Gates Foundation’s Committee on Single Dose HPV vaccines.
  • CHRISTOPHER ADEYINKA OLUGBENGA ADEYEFA Address: Department of Veterinary Medicine, University of Ibadan, Ibadan, Nigeria

    CHRISTOPHER ADEYINKA OLUGBENGA ADEYEFA Address: Department of Veterinary Medicine, University of Ibadan, Ibadan, Nigeria

    CURRICULUM VITAE Name : CHRISTOPHER ADEYINKA OLUGBENGA ADEYEFA Address: Department of Veterinary Medicine, University of Ibadan, Ibadan, Nigeria. Tel: +234-2-8103168, +234-2-7502572 Fax:+234-2-8i03043 MOBILE; .+234-8034298012, +234-8076527672 Email: [email protected] , [email protected] Date of Birth: 26 May, 1949 Marital Status : Married with children Nationality : Nigerian Present Appointment : Professor since 1st Oct. 1997. University Education and Academic Qualification (a) University of Ibadan, Ibadan, Nigeria: October 1971 - June 1977, Doctor of Veterinary Medicine (DVM). (b) University College of Wales, Aberystwyth, Wales, U.K. September 1981 - December, 1982, M.Sc. (c) University of Ibadan, Nigeria: January 1993 - August 1996, Doctor of Philosophy (Ph.D). Professional Qualifications and Diplomas (a) Diploma in Animal Health, (Distinction Class) June 1970, Animal Health School, Moor Plantation, Ibadan. (b) Doctor of Veterinary Medicine (DVM) June 1977, University of Ibadan. (c) Registered with the Veterinary Council of Nigeria as a Veterinary Surgeon, 1977. Scholarships and Fellowships - Western State (Nigeria) Bursary, and Nigerian Marketing Board (Cocoa) Bursary, 1974 – 1977, for undergraduate studies - British Ministry of Overseas Development (ODA) Fellowship, Sept. 1981 - Dec. 1982 for M.Sc degree. - Commonwealth Academic Staff Fellowship for study/sabbatical leave at the AFRC Institute for Animal Health, Pirbright Laboratory, Pirbright, U.K. Jan - Nov. 1992, for post graduate studies Membership of Learned Societies (a) Member, Nigerian Veterinary Medical Association and other learned societies abroad. Professional, research and employment experience - Aug. 1977 - Aug. 1978: Research Fellow, Nigerian Institute for Trypanosomiasis Research (National Youth Service). Worked on distribution and excretion of isometamidium chloride (samorin) in cattle tissues.
  • Insights Into the Nigerian COVID19 Outbreak Authors

    Insights Into the Nigerian COVID19 Outbreak Authors

    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 9 July 2020 doi:10.20944/preprints202007.0181.v1 Title: Insights into the Nigerian COVID19 outbreak Authors: Chinedu Ugwu A *1, 5, Adewole Adekola *2, Opeoluwa Adewale-Fasoro *3, Oyebola Oyesola *4 Jonathan L. Heeney5, Christian Happi 1, ⁋ Abstract : Given the pace of SARS-CoV-2 transmission and its relatively high mortality rate, COVID-19, has the potential to become the most severe pandemic in recent times. This virus’s spread across international borders has triggered different responses in countries around the globe with a spectrum of mild, moderate to severe outcomes. Nigeria, Africa’s most populous country with many densely populated cities, presents a unique situation for the explosive spread of SARS- CoV-2. However, at the point of this writing, the number of reported confirmed infection and mortality is comparatively lower to other countries with dense urban populations. The exact reasons for this are not clear but include societal, political and infrastructural factors that will influence the course of the outbreak in Nigeria. In this perspective, we have described the ongoing COVID-19 outbreak and its associated peculiarities. We identify critical steps that remain to be taken to contain and control the outbreak in Nigeria. Keywords: Nigeria, disease drivers, public health, COVID19 Affiliations: 1 Africa Centre of Excellence for Genomics of Infectious Disease, Redeemers’ University Ede, Osun State Nigeria 2 Royal Veterinary College, University of London, United Kingdom 3 Johns Hopkins Bloomberg School of Public Health, Baltimore, USA 4 Cornell University, Ithaca, NY 14850, United States and University of Washington, Seattle, WA, 98106, United States 5.
  • West Africa Genomics Research

    West Africa Genomics Research

    West Africa Ge nomics Research (WAGER) Network Characterizing Fevers of Unknown Origin (FUO) Through Microbial Metagenomics PI: Christian Happi Co-PI: Onikepe Folarin WAGER 2013 WAGER Network Redeemer’s University, Nigeria AFRICAN UNIVERSITY PARTNERS Redeemer’s University, Nigeria INTERNATIONAL Irrua Specialist Teaching Hospital, RESEARCH/TRAINING Nigeria Technology PARTNERS The Broad Institute of Harvard Universite Cheik Anta Diop, Transfer/Tr and MIT, Boston, USA Senegal aining/Sup port University of Sierra Leone, Sierra Harvard University, USA Leone WAGER 2013 Tulane University, USA OVERALL AIM Employ the power of new technologies and analytic methods for the benefit of patients and community caretakers. WAGER 2013 Objectives • Develop a rapid, field deployable, low cost and flexible diagnostic system for: – FUO causing diseases – Known drug resistance markers for malaria – Novel pathogens detected through high throughput metagenomic sequencing. • Develop Capacity in West African Institutions WAGER 2013 Develop Capacity in Genomics in West African Institutions – Transfer of technology in the area of genomics – Train personnel in area of genomics – Support and promote cutting edge genomics research on health in West Africa WAGER 2013 Introduction and Significance • High prevalence of infectious diseases in developing countries • All infectious pathogenic disease have common symptoms • Diagnosis possible only by culturing or targeted molecular approaches • This is challenging and problematic especially in developing countries WAGER 2013 • Better tool such as Microbial Metagenomics is therefore required for pathogen discovery in fever of unknown origin (FUO). – Is the unbiased characterisation of microbial nucleic acids. – does not require culturing. – No cloning. – a priori knowledge of the infecting microbes. WAGER 2013 • Better tool such as Microbial Metagenomics is therefore required for pathogen discovery in fever of unknown origin (FUO).
  • Retrospective Cohort Study of Lassa Fever in Pregnancy, Southern Nigeria Sylvanus Okogbenin, Joseph Okoeguale, George Akpede, Andres Colubri, Kayla G

    Retrospective Cohort Study of Lassa Fever in Pregnancy, Southern Nigeria Sylvanus Okogbenin, Joseph Okoeguale, George Akpede, Andres Colubri, Kayla G

    RESEARCH Retrospective Cohort Study of Lassa Fever in Pregnancy, Southern Nigeria Sylvanus Okogbenin, Joseph Okoeguale, George Akpede, Andres Colubri, Kayla G. Barnes, Samar Mehta, Reuben Eifediyi, Felix Okogbo, Joseph Eigbefoh, Mojeed Momoh, Mojeed Rafiu, Donatus Adomeh, Ikponmwosa Odia, Chris Aire, Rebecca Atafo, Martha Okonofua, Meike Pahlman, Beate Becker-Ziaja, Danny Asogun, Peter Okokhere, Christian Happi, Stephan Günther, Pardis C. Sabeti, Ephraim Ogbaini-Emovon In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at http://www.medscape.org/journal/eid; and (4) view/print certificate.
  • Curriculum Vitae of Onikepe Abiola Folarin A

    Curriculum Vitae of Onikepe Abiola Folarin A

    CURRICULUM VITAE OF ONIKEPE ABIOLA FOLARIN A. PERSONAL DATA: 1. Name: FOLARIN Onikepe Abiola 2. Date of Birth: 25th September, 1973 3. Marital Status: Married 4. Postal Address: Department of Biological Sciences, College of Natural Sciences, Redeemer’s University. P.M.B. 203, Ede, Osun State, Nigeria 5. Email Address: [email protected] 6. Mobile phone numbers: (234) 803 565 9134 7. No. of children and their ages: Two (2) children (Fifteen and Eleven years) 8. Name and address of Spouse: Mr. Olalekan Adebisi Folarin, No. 6 Joseph Adediran Way off Basorun Road, Ibadan, Oyo State 9. Name and address of Next of Kin: Mr. Olalekan Adebisi Folarin No. 6 Joseph Adediran Way off Basorun Road, Ibadan, Oyo State 10. Nationality: Nigerian 11. State of Origin: Oyo State B. EDUCATIONAL BACKGROUND: 1. Higher Educational Institutions attended with dates: o University of Ibadan, Ibadan 2000 – 2006 o University of Ibadan, Ibadan 1998 – 1999 o University of Ibadan, Ibadan 1991 – 1997 1 2. Academic and Professional Qualifications: Academic Qualification o Ph.D. (Biochemistry/Molecular Biology) 2006 o M. Sc. (Biochemistry) 1999 o B.Sc. (Biochemistry) 1997 Professional Qualification o Advanced Molecular Biology Training Course 2007 o Molecular Biology and Genomics training course 2014 o MiSeq Next Generation Sequencing Training 2015 o Advanced Genomics Training Course 2015 o MalariaX: Defeating Malaria from the Genes to the Globe 2017 3. Other Distinctions and Awards: o WHO/TDR award for Malaria Molecular Biology Training 2002 Workshop/course, Kampala, Uganda o Nigeria Federal Government Postgraduate Scholarship 2002 o MIM Travel Award for the 4th MIM Pan-African Conference on 2005 Malaria o UNCTAD Fellowship for Advanced Molecular Biology Training 2007 Course in Cape Town, South Africa o Boroughs Wellcome and Bill and Melinda Gates Awards, Genome 2010 Epidemiology Meeting (GEM), Wellcome Trust Conference Centre, Hinxton, UK.

  • Current Trends of Yellow Fever in Nigeria: Challenges and Prospects

    UJMR, Volume 4 Number 2, December, 2019, pp 64 - 69 ISSN: 2616 – 0668 https://doi.org/10.47430/ujmr.1942.011 Received: 19/11/2019 Accepted: 4/12/2019 Current Trends of Yellow Fever in Nigeria: Challenges and Prospects Abdulkadir B.1, Dazy D.B.2, Abubakar M. A.2, Farida A.T.2, Samira I.G.2, Aladelokun J. D.2,Nafisat S. T.2, Olaosebikan V. O.2, Ibrahim E.2, Samira A.2, and Nwadigwe M. O.2 1 Department of Microbiology Umaru Musa Yaradua University Katsina 2 Department of Microbiology Kebbi State University of Science and Technology Aliero *Corresponding Author: [email protected] Abstract Yellow fever is a viral infection caused by yellow fever virus and is spread by the bite of an infected female mosquito (Aedes and Haemogogus species). The evolutionary origin of yellow fever lies in Africa, with transmission of the disease from nonhuman primates to human. Yellow fever remains a disease of significant public health importance. The earliest outbreak of yellow fever in Nigeria was reported in Lagos in 1864 with subsequent regular outbreaks reported until 1996 following which Nigeria has been responding to successive outbreaks. Since 15th September 2017, when the Nigeria Centre for Disease Control (NCDC) officially notified a confirmed case of yellow fever in Kwara state to WHO as per the International Health Regulations (2005). Currently the country has been responding to successive yellow fever outbreaks over a wide geographic area. As such, four-year (2018-2021) national yellow fever Preventive Mass Vaccination Campaign (PMVC) plan, supported by the Global Alliance for Vaccines and Immunization (GAVI) and partners, is currently being implemented to cover all states in the country.